In this article, in addition to proving that the 753b degrader has a potent antileukemia effect in primary patient‐derived AML blasts and in vivo activity in an AML‐derived patient‐derived xenograft model, it was found that it does not degrade BCL‐2 as readily as it degrades BCL‐xl.104. The gene discussed is BCL2L1; the disease is acute myeloid leukemia.